NCT02117817 2022-07-28Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian CancerRutgers, The State University of New JerseyPhase 1 Withdrawn
NCT01623349 2021-02-10Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerDana-Farber Cancer InstitutePhase 1 Completed118 enrolled